<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854512</url>
  </required_header>
  <id_info>
    <org_study_id>ANJ900D3501</org_study_id>
    <nct_id>NCT04854512</nct_id>
  </id_info>
  <brief_title>Investigational Study of Delayed Release Metformin</brief_title>
  <acronym>DREAM-T2D</acronym>
  <official_title>Randomized, Multicenter, Double-blind, Parallel-Group, Placebo &amp; Comparator-Controlled Study to Compare the Glycemic Effects, Safety &amp; Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anji Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anji Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Phase 1 and 2 studies already conducted, Metformin DR, with its targeted delivery to the&#xD;
      distal small intestine, has shown the potential to be a safe and effective way to improve&#xD;
      glycemic control in patients with T2DM and CKD with less systemic metformin exposure. The&#xD;
      primary purpose of this Phase 3 clinical study is to collect pivotal data confirming the&#xD;
      safety and efficacy of Metformin DR in T2DM patients with varying renal function from normal&#xD;
      up to CKD3B.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicenter, international study with a 28 week randomized, double blind&#xD;
      parallel group, placebo and active comparator controlled period and a 24 week open label&#xD;
      extension period in patients with T2DM who are treated with metformin at the time of study&#xD;
      screening.&#xD;
&#xD;
      Approximately 675 patients will be randomly assigned to 1 of 3 treatment groups. The study&#xD;
      will assess change in HbA1c through 28 weeks for Metformin DR compared to placebo as a&#xD;
      primary endpoint. In addition, assessments of change in HbA1c for Metformin DR compared to&#xD;
      Metformin IR and assessment of absolute change in HbA1c will be evaluated in the study.&#xD;
&#xD;
      Screening and Run-in Period:&#xD;
&#xD;
      The study will include an up to 10-day screening period, an 4 to 8-week metformin washout&#xD;
      period, and a 2-week single blind (patient blinded) placebo run-in period.&#xD;
&#xD;
      Treatment Period:&#xD;
&#xD;
      Patients that are determined eligible based upon the screening and run-in criteria will enter&#xD;
      the 28-week double-blind treatment period. During the double-blind treatment period, patients&#xD;
      will be randomly assigned to 1 of 3 treatment groups (Group A, B, or C) in a 1:1:1 ratio. The&#xD;
      3 treatments are Metformin DR (1800 mg Metformin DR with matching placebo for Metformin IR),&#xD;
      Metformin IR (1500 mg Metformin IR with matching placebo for Metformin DR), and placebo&#xD;
      (matching placebo for Metformin IR with matching placebo for Metformin DR). For those&#xD;
      patients randomized to Metformin IR, their Metformin IR dose will be titrated to prevent&#xD;
      gastrointestinal intolerability:&#xD;
&#xD;
      Open Label Extension Period:&#xD;
&#xD;
      Upon completion of the 28 week treatment patients will be eligible for an additional 24 weeks&#xD;
      of open label extension period where assigned study treatment will continue and additional&#xD;
      efficacy, safety and tolerability data will be collected and analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline to 28 weeks</time_frame>
    <description>Change in HbA1c in patients treated with Metformin DR compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c response (Metformin DR vs. placebo)</measure>
    <time_frame>Baseline to 28 weeks</time_frame>
    <description>HbA1c absolute value-based response (Yes/No) at Week 28 defined as HbA1c ≤7% for Metformin DR compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (Met DR vs. metformin IR)</measure>
    <time_frame>Baseline to 28 weeks</time_frame>
    <description>Change in HbA1c from the double-blind treatment period baseline to Week 28 for Metformin DR compared to Metformin IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c response (Metformin DR vs. metformin IR)</measure>
    <time_frame>Baseline to 28 weeks</time_frame>
    <description>HbA1c absolute value-based response (Yes/No) at Week 28 defined as HbA1c ≤7% for Metformin DR compared to Metformin IR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">675</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Investigational Arm (Metformin DR plus metformin IR placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A will receive 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2×placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm (Metformin DR placebo plus metformin IR placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B will receive placebo for 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2× placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control Arm (Metformin DR placebo plus metformin IR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C will receive placebo for 1800 mg Metformin DR qAM + 1500 mg metformin IR in divided doses (2× metformin IR 500 mg qAM and 1× metformin IR 500 mg qPM).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin DR</intervention_name>
    <description>Delay-Release Metformin</description>
    <arm_group_label>Investigational Arm (Metformin DR plus metformin IR placebo)</arm_group_label>
    <other_name>ANJ900</other_name>
    <other_name>MetDR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin IR</intervention_name>
    <description>Immediate Release Metformin</description>
    <arm_group_label>Active Control Arm (Metformin DR placebo plus metformin IR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin DR Placebo</intervention_name>
    <description>Metformin DR Placebo</description>
    <arm_group_label>Active Control Arm (Metformin DR placebo plus metformin IR)</arm_group_label>
    <arm_group_label>Placebo Arm (Metformin DR placebo plus metformin IR placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin IR placebo</intervention_name>
    <description>Metformin IR placebo</description>
    <arm_group_label>Investigational Arm (Metformin DR plus metformin IR placebo)</arm_group_label>
    <arm_group_label>Placebo Arm (Metformin DR placebo plus metformin IR placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is male or female and at least 18 years old&#xD;
&#xD;
          2. Has body mass index 20.0 to 45.0 kg/m2 (inclusive)&#xD;
&#xD;
          3. Has T2DM&#xD;
&#xD;
          4. Has HbA1c of 7.0% to 9.5%, inclusive, at Visit 1A and HbA1c value of 7.0% to 10.5%,&#xD;
             inclusive, at Week -2 (Visit 3/3A as applicable)&#xD;
&#xD;
          5. Has an eGFR value of ≥30 mL/min/1.73 m2 based on the CKD-EPI equation at Visit 1A and&#xD;
             Visit 3/3A (Week -2)&#xD;
&#xD;
          6. Stable treatment with a metformin preparation or a combination product containing&#xD;
             metformin for 8 weeks prior to Visit 1A&#xD;
&#xD;
          7. If treated with the following medications, must be on a stable regimen for a minimum&#xD;
             of 6 weeks prior to Visit 1B&#xD;
&#xD;
               1. Drugs known to affect body weight, including prescription medications (e.g.,&#xD;
                  phentermine, phentermine/topiramate, orlistat, lorcaserin, bupropion/naltrexone)&#xD;
                  and over-the-counter anti-obesity agents&#xD;
&#xD;
               2. Hormone replacement therapy (female patients) and testosterone (male patients)&#xD;
&#xD;
               3. Oral contraceptives (female patients)&#xD;
&#xD;
               4. Antihypertensive agents including ACEi/ARB&#xD;
&#xD;
               5. Lipid-lowering agents&#xD;
&#xD;
               6. Thyroid replacement therapy&#xD;
&#xD;
               7. Antidepressant agents&#xD;
&#xD;
          8. Ability to understand and willingness to adhere to protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is currently on dialysis, has been on any dialysis within 1 year of Visit 1B, or is&#xD;
             expected to undergo dialysis during the study period&#xD;
&#xD;
          2. Has a history of lactic acidosis&#xD;
&#xD;
          3. Has a fasting plasma glucose (FPG) value &gt;240 mg/dL (&gt;13.3 mmol/L) at Week -2 (Visit&#xD;
             3/3A as applicable)&#xD;
&#xD;
          4. An alanine aminotransferase or aspartate aminotransferase result &gt;2.5 × upper limit of&#xD;
             normal (ULN) or a bilirubin result &gt;1.5 × ULN at Visit 1B or Visit 3/3A (Week -2)&#xD;
             (except in case of documented Gilbert's syndrome)&#xD;
&#xD;
          5. Has a fasting plasma lactate value &gt;2 mol at Visit 1B&#xD;
&#xD;
          6. Has a bicarbonate value ≤20 mEq/L at both Visit 1A and 1B. If bicarbonate value is &lt;20&#xD;
             at Visit 3/3A or 4, patient may be excluded if the investigator considers this&#xD;
             clinically significant&#xD;
&#xD;
          7. A history of &gt;5% weight change within 12 weeks prior to Visit 1A&#xD;
&#xD;
          8. Has mean BP measurements &gt;180 mmHg (systolic BP) or &gt;100 mmHg (diastolic BP) at Visit&#xD;
             1A or Visit 3/3A, which can be rechecked within 1 week (Note: re-screening is allowed&#xD;
             6 weeks after initiation/modification of antihypertensive agents if the patient is&#xD;
             screen failed due to BP only)&#xD;
&#xD;
          9. Oral antidiabetic agent or insulin use that is not stable for 8 weeks prior to&#xD;
             randomization (i.e., change in oral medication dose or basal insulin dose increased or&#xD;
             decreased by more than 20% during the 8 weeks prior to Visit 4 [Day 1])&#xD;
&#xD;
         10. Has been treated, is currently being treated, or is expected to require or undergo&#xD;
             treatment with any of the following excluded medications:&#xD;
&#xD;
               1. Prescribed metformin preparation after initiation of metformin washout following&#xD;
                  Visit 1B&#xD;
&#xD;
               2. Greater than 10 consecutive days of systemic corticosteroids by oral,&#xD;
                  intravenous, or intramuscular route within 12 weeks of Visit 1B; inhaled,&#xD;
                  intranasal, ophthalmic, topical, or intra-articular corticosteroids are not&#xD;
                  exclusionary&#xD;
&#xD;
               3. Planned use of proton pump inhibitors after Visit 2 (Week -6); such use could&#xD;
                  potentially affect the DR and PK of Metformin DR. Proton pump inhibitor treatment&#xD;
                  may be replaced by other treatment (such as H2 receptor antagonists [excluding&#xD;
                  ranitidine], or calcium carbonate antacids) prior to Visit 4 (Day 1), if&#xD;
                  appropriate per the judgment of the Investigator&#xD;
&#xD;
               4. Cationic drugs that are eliminated by renal tubular secretion (e.g., amiloride,&#xD;
                  digoxin, morphine, procainamide, flecainide, quinidine, quinine, ranitidine,&#xD;
                  triamterene, trimethoprim, and vancomycin) within 1 week of Visit 3 (Week 2)&#xD;
&#xD;
               5. Iodinated contrast dye within 1 week prior to Visit 3 (Week -2)&#xD;
&#xD;
               6. Investigational drug within 8 weeks (or 5 half-lives of the investigational drug,&#xD;
                  whichever is greater) of the date of the first dose of randomized study&#xD;
                  medication&#xD;
&#xD;
               7. Metformin DR or double-blind matching placebo for Metformin DR at any time prior&#xD;
                  to Visit 1B&#xD;
&#xD;
         11. Has a clinically significant medical condition as judged by the Investigator that&#xD;
             could potentially affect study participation and/or personal well-being, including but&#xD;
             not limited to the following conditions:&#xD;
&#xD;
               1. Hepatic disease&#xD;
&#xD;
               2. Gastrointestinal disease, including but not limited to:&#xD;
&#xD;
             i. History or presence of inflammatory bowel disease or other severe gastrointestinal&#xD;
             disease, particularly those that may impact gastric emptying, such as gastroparesis&#xD;
             and pyloric stenosis ii. Prior or expected surgical gastrointestinal procedure that&#xD;
             may impact the gut hormonal response to study medication such as gastric bypass&#xD;
             surgery or gastric banding surgery iii. Active diagnosis of pancreatitis c. Endocrine&#xD;
             disorder other than T2DM or hypothyroidism on replacement therapy d. Cardiovascular&#xD;
             disease, including history of stroke, decompensated heart failure New York Heart&#xD;
             Association Class III or IV, myocardial infarction, unstable angina pectoris, or&#xD;
             coronary arterial bypass graft or angioplasty within 3 months prior to Visit 1A&#xD;
             (screening) e. Central nervous system diseases such as epilepsy f. Psychiatric or&#xD;
             neurological disorders that in the Investigator's opinion would cause the patient to&#xD;
             be noncompliant with study procedures g. Organ transplantation h. Chronic or acute&#xD;
             infection requiring systemic antibiotic treatment i. Orthostatic hypotension or&#xD;
             syncope j. Active malignancy within the past 5 years with exception of basal cell and&#xD;
             squamous cell carcinoma&#xD;
&#xD;
         12. Known allergy or hypersensitivity to Metformin DR, Metformin IR, or placebo or any&#xD;
             inactive component of study medication, active comparator, or placebo, unless the&#xD;
             reaction is deemed irrelevant to the study by the Investigator (prior history of&#xD;
             gastrointestinal intolerance to metformin is not exclusionary)&#xD;
&#xD;
         13. Has a history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia&#xD;
             within 1 year prior to Visit 1B&#xD;
&#xD;
         14. A physical, psychological, or historical finding that, in the Investigator's opinion,&#xD;
             would make the patient unsuitable for the study&#xD;
&#xD;
         15. Any verified clinically significant abnormality identified on physical examination,&#xD;
             laboratory tests, ECG, vital signs, or any adverse event (AE) at the time of Visit 1B&#xD;
             through Visit 4 that, in the judgment of the Investigator or any Sub-investigator,&#xD;
             would preclude safe completion of the study or constrains efficacy assessment&#xD;
&#xD;
         16. Currently abuses drugs or alcohol or has a known history of abuse that in the&#xD;
             Investigator's opinion would cause the patient to be noncompliant with study&#xD;
             procedures&#xD;
&#xD;
         17. Had a blood transfusion or experienced significant blood loss (i.e., &gt;500 mL),&#xD;
             including loss due to blood donation, within 8 weeks prior to Visit 1B, or is planning&#xD;
             to donate blood or have a blood transfusion during the study&#xD;
&#xD;
         18. Prior or planned major surgery of any kind (requiring overnight hospitalization)&#xD;
             within 6 months of Visit 1B&#xD;
&#xD;
         19. Patients insufficiently compliant with study medication during the placebo run-in&#xD;
             phase (&lt;85% or &gt;115%) as assessed at Visit 4&#xD;
&#xD;
         20. Is screening for the study at more than one clinical site or is participating in any&#xD;
             other clinical study&#xD;
&#xD;
         21. Is currently pregnant (confirmed by serum pregnancy test at Visit 1B) or breastfeeding&#xD;
             or plans to become pregnant during the course of the study&#xD;
&#xD;
         22. Women of childbearing potential not willing to use highly effective method(s) of birth&#xD;
             control during the entire study, or who are unwilling or unable to be tested for&#xD;
             pregnancy&#xD;
&#xD;
         23. If the patient has evidence of coronavirus disease 2019 (COVID-19) within 2 weeks&#xD;
             prior to enrolment (a positive COVID-19 test or suspicion of COVID-19 infection), the&#xD;
             patient cannot be enrolled in the study&#xD;
&#xD;
         24. Is employed by Anji Pharma (that is an employee, contract worker, or designee of the&#xD;
             company).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Meyers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer - Anji Pharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Donovan</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Program Lead - Anji Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Information Desk</last_name>
    <phone>(617) 861-8605</phone>
    <email>clinicaltrials@anjipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lenzmeier Family Medicine/CCT Research</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaShonda Gilbert</last_name>
      <phone>480-690-5704</phone>
      <email>lashondagilbert@cctresearch.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Lenzmeier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Hughes</last_name>
      <phone>480-588-7752</phone>
      <email>chughes@aventivresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Boren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Horeish, MD</last_name>
      <phone>619-422-2687</phone>
    </contact>
    <investigator>
      <last_name>Adam Horeish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marwa Ahmad</last_name>
      <phone>323-725-0051</phone>
    </contact>
    <investigator>
      <last_name>Mohamed El-Shahawy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Renal Medical Group Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahnilla Khurram</last_name>
      <phone>803-531-2220</phone>
      <phone_ext>2011</phone_ext>
      <email>shahnilla.khurram@valleyrenal.org</email>
    </contact>
    <contact_backup>
      <last_name>Joevani Orellana</last_name>
      <phone>803-531-2220</phone>
      <phone_ext>2011</phone_ext>
      <email>jeovani.orellana@valleyrenal.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sohan Dua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Orange Endocrinology</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria I Marulanda, MD</last_name>
      <phone>407-480-4836</phone>
      <phone_ext>408</phone_ext>
      <email>marines.marulanda@woendo.com</email>
    </contact>
    <contact_backup>
      <last_name>Ineska Freire, MD</last_name>
      <phone>(407) 480-4836</phone>
      <phone_ext>407</phone_ext>
      <email>ineska.freire@woendo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Mandry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute, Inc</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Ramos</last_name>
      <phone>561-802-3060</phone>
      <email>dramos@metabolic-institute.com</email>
    </contact>
    <investigator>
      <last_name>Barry Horowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>In-Quest Medical Research - Peachtree</name>
      <address>
        <city>Peachtree Corners</city>
        <state>Georgia</state>
        <zip>30071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajanikanth Kandula</last_name>
      <phone>770-903-0148</phone>
      <email>raj@inquestmed.com</email>
    </contact>
    <investigator>
      <last_name>Shashank C Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Kelly, RD</last_name>
      <phone>502-214-3990</phone>
      <email>okelly@lmarc.com</email>
    </contact>
    <investigator>
      <last_name>Harold Bays, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Regional Health Services</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Nguyen, MHS</last_name>
      <phone>402-983-8348</phone>
      <email>marianguyen@cctresearch.com</email>
    </contact>
    <investigator>
      <last_name>Tamara Doehner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>505-224-2735</phone>
      <email>recruitment@abqct.com</email>
    </contact>
    <investigator>
      <last_name>Marigene Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Institute for Clinical Research</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Sheets</last_name>
      <phone>910-302-8151</phone>
      <email>volunteers@ci-cr.com</email>
    </contact>
    <investigator>
      <last_name>Yna Oppong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucas Research</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rike Eitner</last_name>
      <phone>252-222-5700</phone>
      <email>info@lucasresearch.org</email>
    </contact>
    <investigator>
      <last_name>Kathryn J Lucas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Nephrology Associates</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Montero, MD</last_name>
      <phone>252-633-9262</phone>
      <email>research@easternnephrology.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Montero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Family Medicine of SayeBrook</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29579</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Claire Amato</last_name>
      <phone>843-293-8850</phone>
      <phone_ext>230</phone_ext>
      <email>mamato@familymedicineofsayebrook.com</email>
    </contact>
    <investigator>
      <last_name>Karen Mahood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Carolina Clinical Research LLC</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moustafa A Moustafa, MD</last_name>
      <phone>803-987-3034</phone>
      <email>mmoustafa@scnephrology.com</email>
    </contact>
    <investigator>
      <last_name>Moustafa A Moustafa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WR-ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Sweet</last_name>
      <phone>423-698-4584</phone>
    </contact>
    <investigator>
      <last_name>Mark McKenzie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galenos Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunice Allen</last_name>
      <phone>972-233-5410</phone>
      <email>info@galenosresearch.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Canadas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrine IPS, PLLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Perea</last_name>
      <phone>713-973-3415</phone>
      <email>perea.research@endocrinecenterhouston.com</email>
    </contact>
    <investigator>
      <last_name>Amer Al-Karadsheh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyotsna Sandil</last_name>
      <phone>703-330-1112</phone>
      <email>jyotsna@andrawis.com</email>
    </contact>
    <investigator>
      <last_name>Nabil Andrawis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Suffolk</city>
        <state>Virginia</state>
        <zip>23435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>888-737-7408</phone>
      <email>contact@iacthealth.com</email>
    </contact>
    <investigator>
      <last_name>David Ramstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

